Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03738878 · ClinicalTrials.gov registry record · Phase 4
Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1
A Phase 4 study, sponsored by Vanderbilt University Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT03738878 is a Phase 4 study that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 4 participants.
The verdict
NCT03738878, a Phase 4 study, was terminated before completion, sponsored by Vanderbilt University Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to test the hypothesis that combined angiotensin receptor blockade (ARB)/neprilysin (NEP) inhibition potentiates the effects of exogenous bradykinin, substance P, and brain natriuretic peptide (BNP) on forearm blood flow or endothelial tissue-type plasminogen activator (t-PA) release compared to ARB alone. A secondary goal is to determine if there is an interactive effect of ARB/NEP inhibition and dipeptidyl peptidase 4 (DPP4) inhibition on responses to these peptides.
Interventions
- DRUG Valsartan
- DRUG LCZ696
- DRUG Bradykinin
- DRUG Substance P
- DRUG BNP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-11-15 |
| Est. Completion | 2024-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03738878
The ClinicalTrials.gov registry entry for NCT03738878 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Valsartan is the first listed.
NCT03738878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03738878 about?
NCT03738878 is a clinical study titled "Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1". The purpose of this study is to test the hypothesis that combined angiotensin receptor blockade (ARB)/neprilysin (NEP) inhibition potentiates the effects of exogenous bradykinin, substance P, and brain natriuretic peptide (BNP) on forearm blood flow or endothelial tissue-type plasminogen activator (...
What is the current status of trial NCT03738878?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2018-11-15. Estimated completion is 2024-12-01.
What interventions are being tested in trial NCT03738878?
The interventions under investigation include: Valsartan (DRUG), LCZ696 (DRUG), Bradykinin (DRUG), Substance P (DRUG), BNP (DRUG).
Who is sponsoring clinical trial NCT03738878?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.